Monoclonal Antibody (mAb)
Monoclonal Antibody and Biosimilars
In the coming years, the biosimilars market is expected to spur a leap of growth due to the fact that several monoclonal antibody (mAb) based drugs are expected to lose their patents from big pharmaceutical manufacturing companies. Some of these patent expiring drugs are Infliximab (Johnson & Johnson), Trastuzumab (Roche), Adalimumab (Abbott), and Cetuximab (Merck) among others. Each one of these drugs have generated billions of dollar of revenues for each of their manufacturer.
After the patents have expired for these drugs the challenge is for the biosimilars manufacturing companies to create a biosimilar drug which is as efficient in effect but at a much lower cost. Currently, it is estimated that approximately 40% of biosimilars under development are mAbs and each of these biosimilars can offer almost 30% reduction in terms of manufacturing costs. With all these factors in consideration, it is of highest and most important concern to the biosimilars manufacturing companies to develop and establish protocols for their production of mAbs in the most efficient way and highest product yield with reduced manufacturing cost.
For a significant length of time, mAbs are manufactured via in vivo production in mice however due to ethical concerns and the need for mAb mass production a demand for high density in vitro production of monoclonal antibodies arises. Bioreactors that can generate high yields of mAbs have been manufactured. However, these bioreactors only allow one mAb production at a time, costly and prone to contamination.
The Esco VacciXcell Advantage
Esco VacciXcell offers a wide range of bioreactors that can produce high yields of mAbs from hundreds of milligrams to grams. The Tide Motion System, which is the main bioprocessing principle of Celcradle™ and TideXcell™, has the following advantages including high cell yield, high product yield, zero shear stress, zero bubbling and foaming, efficient medium consumption, lower space and labor requirements and reduced downstream bioprocessing costs. VacciXcell's bioreactors also boast of its true linear scalability platform where production scale up is as easy as adding equipment but the bioprocessing principles are the same. As a result, bioprocessing time and costs are greatly reduced.